Keros Therapeutics to discontinue cibotercept, announces COO departure

Keros Therapeutics (KROS) announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. As part of this initiative, the company will discontinue all material, internal development activities related to cibotercept. This decision comes after the termination of the development of cibotercept in pulmonary arterial hypertension, following the analysis of all available safety and efficacy data from the TROPOS Phase 2 clinical trial in patients with PAH, which was previously announced on May 29. Keros also announced several board of directors and leadership transitions intended to support the company’s streamlined vision and operational focus. These actions reflect Keros’ confidence in the therapeutic potential of KER-065 and will better enable the company to achieve its mission of delivering meaningful and potentially disease-modifying benefits to patients. Jean-Jacques Bienaime, Keros’ lead independent director, has been appointed as chair of the board, effective August 18. Christopher Rovaldi, president and COO, will cease his employment with Keros, effective August 18. Lorena Lerner is being promoted to chief scientific officer, effective August 6.